Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...